Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1.

The animals receiving the lowest dose of either treatment showed a trend to a higher frequency of deletions associated with larger MH domains than animals receiving the higher doses (Fig. 4E,F ).

also in 53,322 other papers